PRESS RELEASE

Lille, October 15, 2026

FRANCK MOUTHON APPOINTED PRESIDENT OF DIAGAST, FRENCH KEY PLAYER IN THE FIELD OF IMMUNOHEMATOLOGY AND TRANSFUSION SAFETY

Located in the heart of the Eurasanté Health Park, in northern France, DIAGAST has been developing diagnostics solutions for transfusion safety for nearly 40 years. The appointment of Franck Mouthon as President marks a new milestone in the company's development, opening a new chapter for DIAGAST, a subsidiary of the French Blood Establishment (EFS)

Following the Shareholders' General Meeting held on October 2, 2026, DIAGAST announces the appointment of Franck Mouthon as President.

Scientist, entrepreneur and respected leader in the French health innovation ecosystem, Franck Mouthon takes the helm of the company, whose activities contribute to ensuring transfusion safety worldwide every day. His mission will be to drive the company's continued development, promote its scientific, technological and industrial expertise and reinforce DIAGAST contribution to public health and health sovereignty.



I am delighted to join DIAGAST, a French company that brings together outstanding human, scientific, technological, industrial and commercial expertise in a field as strategic as transfusion medicine. My ambition is to unite our teams around a collective project founded on trust, dialogue and commitment, while pursuing the company's strategy and accelerating DIAGAST's international growth . From northern France, we will contribute to a vital public health challenge : ensuring the safety of blood transfusion.

Franck Mouthon, Président of DIAGAST

Communication@diagast.com

PRESS RELEASE

Lille, October 15, 2026

Franck Mouthon has a career dedicated to research and health innovation

Before joining DIAGAST, Franck Mouthon served as Executive Director of the Health Research Programs Agency, led by INSERM since 2024. He was also appointed as an expert member of the monitoring committee of France 2030 Health Innovation Plan.
Elected President of France Biotech in 2019, he played a key role in representing and supporting the French ecosystem of innovative healthcare companies.
As an entrepreneur, he co-founded Theranexus (THX Pharma) in 2013, innovative clinical-stage biopharmaceutical company spun out of the French Alternative Energies and Atomic Energy Commission (CEA), dedicated to developing treatments for rare neurological disorders.
Prior to that, he spent nearly ten years leading a CEA research team dedicated to prion infections.
A graduate of the prestigious École normale supérieure (rue d'Ulm), he holds advanced degree in molecular biology, biochemistry and neuroscience, as well as a diploma in medical virology from Pasteur Institute.

DIAGAST, a French industrial expertise dedicated to transfusion safety


For nearly 40 years, DIAGAST has been developing a scientific and industrial expertise in the field of Immunohematology, a critical discipline that aims to ensure blood compatibility between donors & recipients, thereby contributing to tranfusion safety.

The company has mastered a range of diagnostic technologies and has developed recognized expertise in the bioproduction of monoclonal antibodies. Its solutions support healthcare professionals in their immunohematology diagnostic activities and contribute to patient safety.


Through its research and manufacturing activities, DIAGAST contribute to the vitality of the regional healthcare industry ecosystem. Its expertise helps preserve stretgic capabilities in France while strengthening the international influence of French healthcare technologies.

Subsidiary of the French Blood Establisment (EFS), DIAGAST, created in 1988, is a French company specialized in conception, manufacturing and marketing of reagents, automated systems and diagnostics solutions in Immunohematology and transfusion medicine.

With more than 250 people, DIAGAST has a commercial presence in more than 100 countries worldwide. Over 70% of its revenue is generated from international markets and 9 % is invested in research and development.







Communication@diagast.com